P86.01 Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC

Up-regulation of AXL tyrosine kinase expression is observed various tumor types including EGFR-mutant (EGFRm) NSCLC with progressive disease on EGFR tyrosine kinase inhibitors (TKIs), especially in a T790M negative population. Xenograft studies have demonstrated that combined inhibition of AXL and EGFR can overcome and delay the onset of resistance. Phase 1 studies of DS-1205c, which is a novel, orally administered, highly selective small molecule inhibitor of AXL, in combination with EGFR TKIs are being conducted in patients with EGFRm NSCLC.